Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 9133253
Ricin vaccine and methods of making thereof
granted -
US 9133250
Proteins with repetitive bacterial-Ig-like (Big) domains present in Leptospira species
granted -
US 9128080
Modified T cell receptors and related materials and methods
granted -
US 9127056
Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
granted -
US 9125923
Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
granted -
US 9120867
Lutzomyia longipalpis polypeptides and methods of use
granted -
US 9120967
Concentric forster resonance energy transfer relay for the parallel detection of two bio/physicochemical process
granted -
US 9119828
Antibodies with simultaneous subsite specificities to protein and lipid epitopes
granted -
US 9120868
Recombinantly expressed Plasmodium CelTOS antigen and methods of use thereof
granted -
US 9114151
Method for modulating or controlling sodium channel current by reactive oxygen species (ROS) originating from mitochondria
granted -
US 9115094
Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
granted -
US 9115205
Plasmodium falciparum circumsporozoite vaccine gene optimization for soluble protein expression
granted -
US 9114102
Method of inhibiting ABCG2 and related treatments
granted -
US 9115371
Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
granted -
US 9115187
Identification of antibodies specific for lyssaviruses and methods of their use
granted -
US 9107866
Adhesin-enterotoxin chimera based immunongenic composition against enterotoxigenic Escherichia coli
granted -
US 9107938
Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
granted -
US 9102752
Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
granted -
US 9101582
Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen
granted -
US 9102660
Process of making prostacyclin compounds with linker thiol and pegylated forms
granted -
US 9101600
Compounds as RORΞ³t modulators and uses thereof
granted -
US 9101601
Methods of treating or preventing insulin resistance and associated diseases and conditions
granted -
US 9102831
Process for producing improved zein articles
granted -
US 9095539
Anti-adhesin based passive immunoprophylactic
granted -
US 9095597
N-acetyl mannosamine as a therapeutic agent
granted -
US 9097713
Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus
granted -
US 9096653
Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
granted -
US 9089515
Long chain N-alkyl compounds and oxa-derivatives thereof
granted -
US 9090873
Development of dengue virus vaccine components
granted -
US 9084820
Magnetic microstructures for magnetic resonance imaging
granted -
US 9084783
Thio compounds
granted -
US 9085604
Antiproliferative factor and methods of use
granted -
US 9084819
Magnetic microstructures for magnetic resonance imaging
granted -
US 9084809
Immunogenic capsule composition for use as a vaccine component against Campylobacter jejuni
granted -
US 9084761
Use of interleukin-15 to treat cardiovascular diseases
granted -
US 9079936
Derivatives of APF and methods of use
granted -
US 9079974
GH-RH analogs with potent agonistic effects
granted -
US 9074195
Nanoparticle entrapment of materials
granted -
US 9074185
Adoptive cell therapy with young T cells
granted -
US 9072767
Anti-regurgitation and/or anti-gastrooesophageal reflux composition, preparation and uses
granted -
US 9072716
Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells
granted -
US 9072709
Enhancement of bone morphogenic protein (BMP) retention with BMP binding peptide (BBP)
granted -
US 9068165
Therapeutic applications of P53 isoforms in regenerative medicine, aging and cancer
granted -
US 9066948
Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines
granted -
US 9068003
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
granted -
US 9066965
Purified limonin glucoside for prevention and treatment of chronic diseases
granted -
US 9056891
Synthetic peptide inhibitors of Wnt pathway
granted -
US 9056068
Vaccine and methods of use against Strongyloide stercoralis infection
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory